Edwards Lifesciences Corp
NYSE:EW

Watchlist Manager
Edwards Lifesciences Corp Logo
Edwards Lifesciences Corp
NYSE:EW
Watchlist
Price: 75.38 USD 0.76% Market Closed
Market Cap: 44.5B USD
Have any thoughts about
Edwards Lifesciences Corp?
Write Note

Gross Margin
Edwards Lifesciences Corp

78.6%
Current
78%
Average
47.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
78.6%
=
Gross Profit
4.4B
/
Revenue
5.6B

Gross Margin Across Competitors

Country US
Market Cap 44.5B USD
Gross Margin
79%
Country US
Market Cap 199B USD
Gross Margin
56%
Country US
Market Cap 191.3B USD
Gross Margin
67%
Country US
Market Cap 141.3B USD
Gross Margin
64%
Country US
Market Cap 134.2B USD
Gross Margin
69%
Country IE
Market Cap 104.6B USD
Gross Margin
65%
Country US
Market Cap 65.6B USD
Gross Margin
45%
Country DE
Market Cap 58.1B EUR
Gross Margin
38%
Country CN
Market Cap 312.8B CNY
Gross Margin
64%
Country US
Market Cap 36.1B USD
Gross Margin
41%
Country US
Market Cap 34.1B USD
Gross Margin
58%
No Stocks Found

Edwards Lifesciences Corp
Glance View

Market Cap
44.5B USD
Industry
Health Care
Economic Moat
None

Nestled at the intersection of medical innovation and patient care, Edwards Lifesciences Corp. has long been a pioneer in the field of heart disease solutions. Emerging from its origins in the 1950s, the company has consistently focused on advancing heart valve technology, a critical area given the prevalence and severity of cardiovascular diseases. Their journey began with the development of the first artificial heart valve, setting a foundation of innovation that continues to propel the company forward. Today, Edwards is renowned for its leadership in transcatheter aortic valve replacement (TAVR) technology, an area that revolutionizes the treatment of aortic stenosis, a condition that narrows heart valves and impedes blood flow. This shift from open-heart surgeries to less invasive procedures, facilitated by Edwards' products, has marked a significant turning point in patient care, minimizing recovery times and enhancing patient outcomes. Financially, Edwards Lifesciences thrives on a robust business model centered around its technologically advanced heart valve systems and critical care technologies. The company operates through a direct sales force as well as strategic partnerships, ensuring their devices reach hospitals and healthcare providers globally. Their commitment to research and development ensures a steady pipeline of innovative products, which not only differentiates them in the market but also drives their profitability. Revenue streams are primarily fueled by the sales of their TAVR systems, surgical heart valves, and monitoring technologies—each designed to meet the complex and evolving needs of patients with structural heart diseases. By continually investing in cutting-edge technology and expanding their global reach, Edwards Lifesciences not only supports its bottom line but also positions itself as a leader in the transformative field of medical device innovation.

EW Intrinsic Value
55.54 USD
Overvaluation 26%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
78.6%
=
Gross Profit
4.4B
/
Revenue
5.6B
What is the Gross Margin of Edwards Lifesciences Corp?

Based on Edwards Lifesciences Corp's most recent financial statements, the company has Gross Margin of 78.6%.